Novel neurotrophin-based strategies to promote central nervous system remyelination
Grant number: 13-039 | Funding period: 2014 - 2015
Given that ADP is a purinergic agonist released from platelet dense granules, and hence contained in any PRP preparation for bone application, it is clinically relevant to investigate the role of this molecule upon osteoblast function in both immature and mature cells. Furthermore, P2Y12 antagonists are used for prevention of thrombosis and ischemic events, but have a potential negative effect on bone. The possibility of local application of a P2Y12 agonist to accelerate bone formation may have therapeutic potential. Therefore, further characterization of P2Y12 purinergic signaling through ADP in relation to bone formation is critical.